NK012

NK012 is a nanoparticle drug delivery system that is used to deliver SN-38, the active metabolite of Irinotecan. It was developed by Nippon Kayaku.

Mechanism of action[edit | edit source]

NK012 is a polymer-drug conjugate that uses a polyglutamic acid (PGA) polymer to deliver SN-38. The PGA polymer is linked to SN-38 via a ester bond, which is cleaved in the body to release the active drug. The nanoparticle formulation allows for a higher concentration of the drug to be delivered to tumor cells, while reducing the exposure of healthy cells to the drug.

Clinical trials[edit | edit source]

NK012 has been tested in clinical trials for various types of cancer, including colorectal cancer, non-small cell lung cancer, and ovarian cancer. In a phase I clinical trial, NK012 showed promising results in patients with advanced solid tumors. However, in a phase II clinical trial for non-small cell lung cancer, the drug did not meet its primary endpoint of improving progression-free survival.

Side effects[edit | edit source]

The most common side effects of NK012 are neutropenia, diarrhea, and fatigue. Severe neutropenia was reported in a significant number of patients in clinical trials.

See also[edit | edit source]

NK012 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.